November 27, 2020
Latham & Watkins advised
ATAI Life Sciences, a global biotech platform, in raising US$125 million in a
Series C financing round.
The financing was led by Apeiron
Investment Group, Peter Thiel and Catalio Capital Management.
Proceeds from the financing will
be used primarily to fund pre-clinical and clinical development of ATAI's
existing mental health programs, to expand its drug candidate pipeline and
further advance ATAI's platform technologies.
The Latham team was led by
London corporate partner Robbie McLaren and Frankfurt corporate partner Markus
Krueger, with associates Jon Fox and David Funken.